LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

LLY

986.45

+0.17%↑

JNJ

242.9

+0.54%↑

ABBV

221.34

+0.76%↑

NVS

154.3

+0.79%↑

AZN

191.97

+0.98%↑

Home・Akcijų sąrašas・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Uždarymo kaina

15.58 2.1

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

15.25

Max

15.88

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-2.2M -10M
Darbuotojai	31
EBITDA	131K -10M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+108.88% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-07

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	759M 1.3B
Ankstesnė atidarymo kaina	13.48
Ankstesnė uždarymo kaina	15.58

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bearish Evidence

3.165 / 3.5827 Palaikymas ir pasipriešinimas

Corvus Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions -2-

2026-03-15 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Central Bank Decisions in Focus After Jump in Energy Prices

2026-03-16 00:00; UTC

Svarbiausios naujienos

Hack on U.S. Medical Company Shows Reach of Iran's Cyber Capabilities -- WSJ

2026-03-15 23:45; UTC

Rinkos pokalbiai

Nikkei May Decline on Concerns About Prolonged Middle East Conflict -- Market Talk

2026-03-15 23:44; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls as Rising Energy Prices Exacerbate Inflation Worries -- Market Talk

2026-03-15 23:35; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Futures Rise on Supply Disruption Concerns -- Market Talk

2026-03-15 23:00; UTC

Įsigijimai, susijungimai, perėmimai

Micron Completes Acquisition Of PSMC's Tongluo P5 Site In Taiwan >MU

2026-03-15 22:37; UTC

Rinkos pokalbiai

March Rate Hike Would Distance RBA From Government's May Budget -- Market Talk

2026-03-15 22:18; UTC

Rinkos pokalbiai

RBA's Likely Hike Motivated By Inflation, Not Middle East -- Market Talk

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Adj Net $230.35M Vs. Adj Net $59.83M>1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Loss Due to High Base Effect, One-off Unrealized Gains Seen Last Year >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Rev $959.53M Vs. $594.49M >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech 2025 Loss $532.83M Vs. Net $2.96B >1548.HK

2026-03-15 22:14; UTC

Uždarbis

Genscript Biotech: 2025 Rev Supported by Substantial Increase in License Revenue>1548.HK

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 22:00; UTC

Svarbiausios naujienos

Oil Industry Warns Trump Administration Energy Crisis Will Likely Worsen -- WSJ

2026-03-15 03:00; UTC

Svarbiausios naujienos

For Xi, Iran War Reinforces View of U.S. as Dangerous Superpower -- WSJ

2026-03-14 15:00; UTC

Svarbiausios naujienos

Iran War Delivers Windfall to America's Oil Country -- WSJ

2026-03-14 02:03; UTC

Uždarbis

This Copper Stock Is Worth Mining for Profits -- Barrons.com

2026-03-14 01:32; UTC

Įsigijimai, susijungimai, perėmimai

Bill Ackman's Pershing Square IPO Is Back On -- Barrons.com

2026-03-14 00:29; UTC

Įsigijimai, susijungimai, perėmimai

13D Filings -- Barrons.com

2026-03-13 22:27; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Bahrain Faces Uncertainty But Has Support Amid War, S&P Says -- Market Talk

2026-03-13 22:13; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Saudi Arabia Seen as Able to Weather Iran Conflict, S&P Says -- Market Talk

2026-03-13 22:04; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Emirate of RAK Outlook Stable Despite Iran War, S&P Says -- Market Talk

2026-03-13 22:00; UTC

Įsigijimai, susijungimai, perėmimai

Trump Administration Set to Receive $10 Billion Fee for Brokering TikTok Deal -- WSJ

2026-03-13 20:50; UTC

Rinkos pokalbiai

Health Care Roundup: Market Talk

2026-03-13 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-03-13 20:02; UTC

Rinkos pokalbiai

Canada Rate Hike in 2026 Would Mark 'Extraordinarily Bad' Policy -- Market Talk

2026-03-13 19:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains As Middle East Conflict Drags On -- Market Talk

2026-03-13 19:35; UTC

Svarbiausios naujienos

Oil Prices Hover Near $100. India Asks Iran to Allow 23 Tankers Through Strait of Hormuz. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Corvus Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

108.88% į viršų

12 mėnesių prognozė

Vidutinis 32 USD 108.88%

Aukščiausias 42 USD

Žemiausias 27 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Corvus Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Corvus Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

3.165 / 3.5827Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

All events are bearish.

Bearish events outweigh bullish events.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.